Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma

Tas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E.

LUNG CANCER, vol.57, no.1, pp.79-83, 2007 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 57 Issue: 1
  • Publication Date: 2007
  • Doi Number: 10.1016/j.lungcan.2007.02.009
  • Journal Name: LUNG CANCER
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.79-83
  • Istanbul University Affiliated: Yes


Background: Topotecan is an active agent for the management of untreated and recurrent extensive-disease small cell tung cancer, (ED-SCLC). This study was designed to evaluate the efficacy and safety of a triplet combination with topotecan added to the standard PE regimen in previously untreated patients with ED-SCLC.